Susquehanna International Group
QNCX icon

Susquehanna International Group’s Quince Therapeutics QNCX Stock Holding History

Susquehanna International Group’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.5K Sell
863
-862
-50% -$173K ﹤0.01% 12876
2025
Q4 		$1.16M Buy
+1,725
New +$868K ﹤0.01% 6860
2024
Q4 		– Sell
-163
Closed -$49K – 13018
2024
Q3 		$25.3K Sell
163
-330
-67% -$47.3K ﹤0.01% 11576
2024
Q2 		$74K Buy
493
+9
+2% +$1.63K ﹤0.01% 11216
2024
Q1 		$103K Sell
484
-16
-3% -$3.98K ﹤0.01% 11199
2023
Q4 		$105K Sell
500
-20
-4% -$4K ﹤0.01% 11291
2023
Q3 		$116K Sell
520
-44
-8% -$11.5K ﹤0.01% 10789
2023
Q2 		$170K Sell
564
-64
-10% -$19.9K ﹤0.01% 10448
2023
Q1 		$196K Buy
628
+108
+21% +$21.1K ﹤0.01% 10619
2022
Q4 		$66.3K Sell
520
-378
-42% -$63.2K ﹤0.01% 11239
2022
Q3 		$239K Buy
898
+144
+19% +$54.9K ﹤0.01% 10394
2022
Q2 		$335K Buy
754
+100
+15% +$70.7K ﹤0.01% 9273
2022
Q1 		$809K Sell
654
-1,771
-73% -$2.41M ﹤0.01% 7693
2021
Q4 		$6.12M Buy
2,425
+2,130
+722% +$13M ﹤0.01% 3419
2021
Q3 		$5.41M Buy
295
+54
+22% +$859K ﹤0.01% 3812
2021
Q2 		$2.55M Sell
241
-160
-40% -$1.34M ﹤0.01% 5379
2021
Q1 		$2.89M Buy
+401
New +$2.89M ﹤0.01% 5051

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Susquehanna International Group's QNCX Position: Q1 2026 in Review

Susquehanna International Group reduced its Quince Therapeutics (QNCX) stake by 50% in Q1 2026, selling an estimated $173K and leaving 863 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #12876.

Susquehanna International Group first reported a position in QNCX in Q1 2021 and has held it in 17 quarters since. The position peaked at $6.12M in Q4 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Susquehanna International Group held 863 shares of Quince Therapeutics worth $17.5K as of Q1 2026.
  • Susquehanna International Group sold 862 Quince Therapeutics shares in Q1 2026, an estimated $173K.
  • Quince Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12876 holding.
  • Susquehanna International Group first reported a position in Quince Therapeutics in Q1 2021 and has held it in 17 quarters since.
  • Susquehanna International Group's Quince Therapeutics position peaked at $6.12M in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.